Laura Walsh underwent six surgeries and was given months to live when she started a Phase II drug trial. Two years later her tumor remains a fraction of the size.
/PRNewswire/ GT Medical Technologies, Inc. announced the enrollment of the first patient into the GESTALT (GammaTile Enhanced Stupp ALTernative Trial) of.